All In MedTech

Device Trial Radar · NCT06832865

ELISA in Relapsed/Refractory MM

A Phase 2 Study of Elranatamab in Combination With Isatuximab (ELISA) in Relapsed and Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Aug 14, 2025

Primary completion

Dec 1, 2026

Study completion Dec 1, 2028

Sponsor

Lead sponsor
Massachusetts General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer; Sanofi
First posted
Feb 18, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label phase 2 study of elranatamab in combination with isatuximab administered subcutaneously in patients with relapsed and refractory multiple myeloma (RRMM) who have received at least one prior line of therapy and who have had previous treatment with both immunomodulatory drugs (IMiDs) and a proteasome inhibitor (PI). The subcutaneous injection method of isatuximab administration, including the device used to administer isatuximab, is investigational.

Conditions

  • Relapsed Refractory Multiple Myeloma (RRMM)
  • Relapsed Refractory Multiple Myeloma

Interventions

  • elranatamabDrug

    Subcutaneously injected study drug, usually into the abdomen or lower stomach. Each vial of elranatamab contains a sufficient amount of product to ensure an extractable volume of 1.9 mL at a concentration of 40 mg/mL. The dosing is as follows: * Cycle 1 Day 1: 12 mg/0.3 mL; * Cycle 1 Day 4: 32 mg/0.8 mL; * Cycle 1 Day 8, 15, 22: 76 mg/1.9 mL; * Cycles 2-6, Day 1 and 15: 76 mg/1.9 mL; * Cycles 7-12, Day 1: 76 mg/1.9 mL; * Cycles 13-24, Day 1 of Cycles 13, 16, 19, 22 (every 12 weeks): 76 mg/1.9 mL

  • Isatuximab SCDrug

    Isatuximab (SAR650984) is an IgG1 derived monoclonal antibody binding selectively the human CD38 membrane protein. Subcutaneously (SC) injected study drug with each vial containing 140 mg/mL (1400 mg/10mL) isatuximab. Isatuximab SC will be injected using the investigational OBDS and in the following doses: * Cycles 2-6, Day 1 and 15: 1400 mg/10 mL * Cycles 7-12, Day 1: 1400 mg/10 mL * Cycles 13-24, Day 1 of Cycles 13, 16, 19, 22 (every 12 weeks): 1400 mg/10 mL

  • Isatuximab SC-OBDSDevice

    The On Body Delivery System (OBDS) also called Isatuximab SC Wearable Injection System, is a sterile, single-use, disposable, elastomeric, user-filled investigational medical device. The OBDD has a reservoir for the drug product (isatuximab). A self-contained, integrated needle (with manual insertion and automatic retraction mechanism) is provided within the OBDS. The OBDS will be used to inject isatuximab each time the participant receives isatuximab in this study. Study drug administration will be done by trained medical professionals in the clinic. The OBDS device will be prepared by the medical professional, placed on the abdomen using the adhesive (sticky) pads that are on the device, the study drug (isatuximab) will be injected, and then the device will be removed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Day 1 to 2 years post-treatment.

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.